Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. for the CDK4/6 inhibitor palbociclib (IBRANCE®).
Erasca was launched on the technologies discovered by Kevan Shokat, PhD, professor and chair in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco.